Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 448,334
  • Shares Outstanding, K 57,040
  • Annual Sales, $ 177,980 K
  • Annual Income, $ -76,910 K
  • 36-Month Beta 1.11
  • Price/Sales 2.53
  • Price/Cash Flow N/A
  • Price/Book 2.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.77
  • Number of Estimates 3
  • High Estimate -0.52
  • Low Estimate -1.13
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -57.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.42 +5.26%
on 08/15/18
10.73 -27.21%
on 07/26/18
-2.48 (-24.10%)
since 07/20/18
3-Month
7.42 +5.26%
on 08/15/18
11.60 -32.67%
on 06/20/18
-2.84 (-26.67%)
since 05/18/18
52-Week
7.42 +5.26%
on 08/15/18
20.25 -61.43%
on 10/02/17
-7.18 (-47.90%)
since 08/18/17

Most Recent Stories

More News
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag

Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.

KERX : 3.12 (+1.96%)
ILMN : 325.99 (+0.03%)
AKBA : 7.81 (-0.64%)
GILD : 72.36 (-0.77%)
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -15.38% and 0.09%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

AKBA : 7.81 (-0.64%)
Akebia Therapeutics Announces Second Quarter 2018 Financial Results

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

KERX : 3.12 (+1.96%)
AKBA : 7.81 (-0.64%)
Akebia Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Akebia Therapeutics, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern Time....

AKBA : 7.81 (-0.64%)
X4 Pharmaceuticals Appoints Michael Wyzga as Chair of Board of Directors

X4 Pharmaceuticals, a clinical-stage biotechnology company developing novel CXCR4 allosteric antagonist drug candidates designed to improve immune cell trafficking to treat...

EXAS : 49.21 (+0.76%)
RDUS : 19.76 (-1.15%)
AKBA : 7.81 (-0.64%)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Keryx Biopharmaceuticals, Inc. to Akebia Therapeutics, Inc. is Fair to Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

KERX : 3.12 (+1.96%)
AKBA : 7.81 (-0.64%)
Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More

Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.

CELG : 90.88 (+0.56%)
CARA : 18.92 (unch)
KERX : 3.12 (+1.96%)
AKBA : 7.81 (-0.64%)
XLRN : 48.08 (-0.64%)
GILD : 72.36 (-0.77%)
AMGN : 197.56 (+0.07%)
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 7.81 (-0.64%)
WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Keryx Biopharmaceuticals Inc. ("KERX" or the "Company") (NASDAQ: KERX) in connection...

KERX : 3.12 (+1.96%)
AKBA : 7.81 (-0.64%)
Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall

Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.

AGLE : 9.16 (-0.43%)
KERX : 3.12 (+1.96%)
AKBA : 7.81 (-0.64%)
ANIP : 56.13 (-0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade AKBA with:

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 8.08
1st Resistance Point 7.95
Last Price 7.81
1st Support Level 7.74
2nd Support Level 7.66

See More

52-Week High 20.25
Fibonacci 61.8% 15.35
Fibonacci 50% 13.84
Fibonacci 38.2% 12.32
Last Price 7.81
52-Week Low 7.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar